BACKGROUND: The antiproteinuric pharmacokinetics of @entity3372 in response to different doses and modalities of administration has been poorly investigated so far. STUDY DESIGN: Prospective, open-label and not placebo controlled study. SETTING AND @entity1 : 40 Caucasian adult @entity1 having GFR  >=   50  mL/min, @entity644 1-3  g/day; @entity13519 / @entity13520   <=  150/90  mmHg were recruited between June 2014 and November 2014. FACTOR AND OUTCOME: Impact on 24  h @entity644 and fractioned @entity644 of @entity3372 given at different dosages (2.5  mg/day or @entity3372 5  mg/day or @entity3372 10  mg/day) and with different daily administration modalities (single or two divided doses) for cycles of 10  days. MEASUREMENTS: At the end of each cycle, 24  h and fractioned @entity644 on three timed urinary collections (morning, afternoon and night) were measured. RESULTS: Compared to baseline, @entity3372 significantly reduced 24  h @entity644 at each dose and modality of administration. In particular, the greatest effects were evident with the higher and divided dose of the drug. The analysis of the fractioned @entity644 showed that the greatest reduction was obtained in the night urinary collection by administering @entity3372 10  mg/day in two divided doses. LIMITATIONS: Small sample size. CONCLUSIONS: @entity3372 reduces @entity644 at any of the tested doses. Although the using of high and divided doses seems to maximize the antiproteinuric effect of the drug, possibly due to a better pharmacological coverage of the nocturnal period.

How to improve duration and efficiency of the antiproteinuric response to XXXX : RamiPROT-a prospective cohort study.

@entity1 :: ('9606', 'Species') :: ['patients', 'PARTICIPANTS'] @entity3372 :: ('MESH:D017257', 'Chemical') :: ['Ramipril'] @entity644 :: ('MESH:D011507', 'Disease') :: ['proteinuria'] @entity13519 :: ('8991', 'Gene') :: ['SBP'] @entity13520 :: ('1628', 'Gene') :: ['DBP']
@entity3372 :: (MESH:D017257,Chemical) :: ['Ramipril']
